Dexlevo Showcases PCL Collagen Stimulator Data at IMCAS 2026
The company presented clinical data on its PCL-based collagen stimulator, positioning it within a shift toward treatments targeting skin laxity.
The company presented clinical data on its PCL-based collagen stimulator, positioning it within a shift toward treatments targeting skin laxity.
The ready-to-use liquid botulinum toxin treatment requires no reconstitution. Phase III trials showed improvements in frown lines, with some patients maintaining results for up to six months.